Blood pressure, albuminuria and renal dysfunction: The 'chicken or egg' dilemma

Nephrology Dialysis Transplantation

Volumn 29, Issue 8, 2014, Pages 1453-1455

  Viazzi, Francesca ^a   Pontremoli, Roberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

ALBUMINURIA; ANIMALS; BLOOD PRESSURE; DISEASE PROGRESSION; HUMANS; HYPERTENSION; RENAL INSUFFICIENCY;

EID: 84904999011     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu183     Document Type: Article

References (23)

1. Pontremoli R, Leoncini G, Ravera M et al. Microalbuminuria, cardiovascular, and renal risk in primary hypertension. J Am Soc Nephrol 2002; 13: S169-S172
2. Viazzi F, Parodi D, Leoncini G et al. Optimizing global risk evaluation in primary hypertension: The role of microalbuminuria and cardiovascular ultrasonography. J Hypertens 2004; 22: 907-913
3. Xu H, Huang X, Cederholm T et al. Urinary albumin excretion, blood pressure changes and hypertension incidence in the community: Effect modification by kidney function. Nephrol Dial Transplant 2014; 29: 1538-1545
4. Guyton AC. Long-Term arterial pressure control: An analysis from animal experiments and computer and graphic models. Am J Physiol 1990; 259 (5 Pt 2): R865-R877
5. Bianchi G, Fox U, Di Francesco GF et al. Blood pressure changes produced by kidney cross-Transplantation between spontaneously hypertensive rats and normotensive rats. Clin Sci Mol Med 1974; 47: 435-448
6. Wang TJ, Evans JC, Meigs JB et al. Low-grade albuminuria and the risks of hypertension and blood pressure progression. Circulation 2005; 111: 1370-1376
7. Brantsma AH, Bakker SJ, de Zeeuw D et al. Urinary albumin excretion as a predictor of the development of hypertension in the general population. J Am Soc Nephrol 2006; 17: 331-335
8. Kestenbaum B, Rudser KD, de Boer IH et al. Differences in kidney function and incident hypertension: The multi-ethnic study of atherosclerosis. Ann Intern Med 2008; 148: 501-508
9. Forman JP, Fisher ND, Schopick EL et al. Higher levels of albuminuria within the normal range predict incident hypertension. J Am Soc Nephrol 2008; 19: 1983-1988
10. Jessani S, Levey AS, Chaturvedi N et al. High normal levels of albuminuria and risk of hypertension in Indo-Asian population. Nephrol Dial Transplant 2012; 27 (Suppl 3): Iii58-iii64
11. Pontremoli R. Microalbuminuria in essential hypertension-its relation to cardiovascular risk factors. Nephrol Dial Transplant 1996; 11: 2113-2115
12. Jensen JS, Feldt-Rasmussen B, Strandgaard S et al. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35: 898-903
13. Olsen MH, Wachtell K, Borch-Johnsen K et al. A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE Study. Losartan Intervention For Endpoint reduction. J Hum Hypertens 2002; 16: 591-595
14. Wachtell K, Ibsen H, Olsen MH et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med 2003; 139: 901-906
15. Pontremoli R, Ravera M, Bezante GP et al. Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. J Hypertens 1999; 17: 993-1000
16. Derchi LE, Leoncini G, Parodi D et al. Mild renal dysfunction and renal vascular resistance in primary hypertension. Am J Hypertens 2005; 18: 966-971
17. Viazzi F, Leoncini G, Conti N et al. Microalbuminuria is a predictor of chronic renal insufficiency in patients without diabetes and with hypertension: The MAGIC study. Clin J Am Soc Nephrol 2010; 5: 1099-1106
18. Leoncini G, Ratto E, Viazzi F et al. Improving cardiovascular risk stratification: The case for redefining microalbuminuria. J Nephrol 2007; 20 (Suppl 12): S51-S55
19. Leoncini G, Sacchi G, Viazzi F et al. Microalbuminuria identifies global cardiovascular risk in essential hypertension: An artificial neural networkbased approach. J Hypertens 2002; 20: 1315-1321
20. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357
21. Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45:198-202
22. Schmieder RE, Mann JF, Schumacher H et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22: 1353-1364
23. Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-1181